Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18810763 | 0.85 | KMT2A (0.33) | GGPS1KMT2AAPOBEC3AAPOBEC3G | |
| SCHEMBL5286663 | 0.82 | APOBEC3A (0.36) | KMT2AAPOBEC3AAPOBEC3G | |
| SCHEMBL5328558 | 0.78 | HTT (0.39) | — | |
| SCHEMBL14227952 | 0.78 | GGPS1 (0.57) | GGPS1KMT2A | |
| SCHEMBL4235579 | 0.78 | GGPS1 (0.53) | GGPS1KMT2A | |
| Bromide SCHEMBL31207551 | 0.76 | GGPS1 (0.51) | GGPS1KMT2A | |
| Hydrochloric Acid SCHEMBL31207622 | 0.76 | GGPS1 (0.51) | GGPS1KMT2A | |
| Bromide SCHEMBL15941512 | 0.76 | GGPS1 (0.51) | GGPS1KMT2A | |
| SCHEMBL18609645 | 0.76 | KDM4E (0.53) | GGPS1 | |
| SCHEMBL5304636 | 0.76 | HTT (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-9242999-B2 | Cephem compound having pyridinium group | SHIONOGI & CO., LTD. (JP) | 2016-01-26 | — | — | US | disclosed |
| US-20140114060-A1 | CEPHEM COMPOUND HAVING PYRIDINIUM GROUP | SHIONOGI & CO., LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140114060-A1 | CEPHEM COMPOUND HAVING PYRIDINIUM GROUP | CEP170, PEPD, CMBL | GGPS1 671/4885KMT2A 1917/4885APOBEC3A 3868/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | GGPS1 2757/4885KMT2A 445/4885APOBEC3A 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.